Bed Bath & Beyond Inc. (NASDAQ:BBBY) shares are trading N/A thus far today and have traded in the range of N/A during the current session. In order to take a look at where the stock might headed longer term, we can also look at different sets of data. Sell-side research firms currently have a consensus one year price target of $41.68 on the stock according to First Call. This number can often vary from the Zacks or FactSet mean targets. The sell-side analysts are projecting earnings per share of $0.76 for the next fiscal quarter. For the current year, analysts are predicting earnings of $4.52 per share according to First Call.
Stock Technicals in Focus
In looking at where the stock is trading on a technical level, the stock is trading +0.02% away from its 50 day moving average of $39.92. Based on the most recent available data, the equity is -23.70% off of its 52-week high of $52.33 and +5.69% away from its 52-week low which is $37.78. In taking a look at the company’s valuation, the firm’s price to earnings ratio stands at 8.48. This is a crucial indicator investors watch as higher ratios compared to peers, would suggest higher future earnings growth potential for the stock. The price to current year EPS estimates from research analysts currently stands at 8.83. In looking further ahead, potential investors should note that the company’s price to next year’s EPS estimates is 8.66.
Today, the stock opened at $N/A and the last bid at the time of writing stood at $39.93. During the session thus far, the equity dipped down to $N/A and touched $N/A as the high point. Bed Bath & Beyond Inc. has a market cap of 5.86B and has seen an average daily volume of 1945120 over the past three months.
Wall Street sell-side research analysts covering Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $21.727 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $45 while the most conservative estimate stand at $9.
Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover Valeant Pharmaceuticals International, Inc.. They give the company shares an ABR of 3.17. This is based on the 11 analysts taken into consideration by Zacks.
Earnings Estimates for Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Currently, Wall Street is projecting that the firm will post $0.99 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2016-12-31, Valeant Pharmaceuticals International, Inc.'s EPS was reported as $1.26. This created a “surprise factor” 1.61% due to being $0.02 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.
Investors will mark their calendars for 2017-06-06, the date when Valeant Pharmaceuticals International, Inc. (NYSE:VRX) are expected to release their quarterly results.